Entities / Company
Gilead Sciences.
American company
- Reports this week
- 7
- Active events
- 5
- Connections
- 320
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Amgen and Gilead Sciences are two companies that compete within the biotech industry.Some support1 report
-
Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Some support2 reports
-
Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.Some support2 reports
-
Benzinga generated content regarding the financial performance of Gilead Sciences on June 17, 2026.Some support2 reports
-
The FDA approved the Bixlenvo HIV regimen developed by Gilead Sciences.Some support1 report
Earlier this month
-
GRAIL and Gilead Sciences, both healthcare companies, are competing for investment.Some support1 report
-
Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Some support4 reports
-
A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.Some support1 report
One to three months ago
-
MarketBeat listed Danaher, Dexcom, Medtronic, Gilead Sciences, and Boston Scientific as stocks to watch on September 22, 2026.Some support5 reports
-
Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.Some support1 report
-
Gilead Sciences established a strategic alliance and contributed $5 billion, while Lakefront Biotherapeutics acquired assets from Ouro Medicines.Some support1 report
-
Gilead Sciences and T. Rowe Price are currently among the largest dividend payers.Some support1 report
-
Analyst upgrades and downgrades were noted for General Motors, Gilead Sciences, Emerson Electric, and CrowdStrike on May 22, 2026.Some support1 report
-
A conference involving Gilead Sciences and Bayer was held in Philadelphia on September 10, 2026.Some support1 report
-
Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.Some support1 report
-
Merdad Parsey, formerly of Gilead Sciences, joined the Sofinnova investment team.Some support1 report
-
Gilead Sciences product acceptance paves way for market access, guided by expert opinion in NHS Scotland.Some support1 report
-
Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.Some support1 report
-
GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.Speculative1 report1 development inside
-
Gilead Sciences provided an HIV prevention drug consignment to a Zambian hospital, funded by the US.Some support1 report
-
Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.Some support1 report
-
FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.Some support1 report
-
Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.Some support2 reports
-
Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.Some support1 report
-
McDonald's, Walmart, and Gilead Sciences are suggested as resilient safe-haven investments during market turmoil.Some support2 reports
-
A lawsuit has been filed regarding the importation of foreign-market drugs, involving Gilead Sciences and Meritain Health, Inc.Some support3 reports1 development inside
-
A U.S. patient case involving Gilead Sciences originated in Turkey, concerning revenue protection from generic imports.Some support1 report
-
Collaboration revenue streams are shared between Sanofi and Gilead Sciences.Some support1 report
-
MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.Some support2 reports
-
Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.Some support1 report
-
Gilead Sciences, Boston Scientific, McKesson Corporation, and Dexcom are listed as top medical stocks.Some support4 reports
-
Norges Bank acquired a new stake in Gilead Sciences, while Boston Partners also bought shares, all filed with the SEC.Some support1 report
-
Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.Some support1 report
-
Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.Some support2 reports
Gone quiet
No new reports in 90+ days-
Top holdings of the IBBQ and IXJ funds were reported, featuring major pharmaceutical companies.Some support3 reports
-
Gilead Sciences sponsored a session at the ESSENCE Festival.Some support1 report
-
The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.Well supported10 reports
-
Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.Some support1 report
-
HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.Some support1 report
-
Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.Some support1 report
-
An investor made multiple stock purchases in companies including Cencora, Gilead Sciences, GE Aerospace, and American Express.Some support1 report
-
Norges Bank acquired a new position in Gilead Sciences shares, triggering institutional ownership filing requirements with the SEC.Some support1 report
-
Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.Well supported3 reports
-
Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.Some support1 report
-
Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.Some support2 reports
-
Phase 3 results showed efficacy in primary biliary cholangitis involving Alp and Gilead Sciences.Some support1 report
-
Gilead Sciences supports Native Son Awards featuring Terrell Carter, with a fellowship debut scheduled in New York.Some support1 report
-
Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.Some support1 report
-
Multiple investment firms, including Paulson Wealth Management and Alpha Cubed Investments, have made various transactions regarding their holdings in Gilead Sciences.Some support1 report
-
Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.Some support1 report1 development inside
-
Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.Some support1 report
-
Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.Some support2 reports
-
U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.Some support2 reports
-
Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.Some support2 reports
-
Gilead Sciences holds the largest shareholder stake in Assembly Biosciences, followed by Alexander Schornstein and The Vanguard Group.Speculative1 report
-
FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.Speculative1 report1 development inside
-
Kymera entered an exclusive option and license agreement with Gilead Sciences.Some support6 reports
-
Gilead Sciences is identified as a participant within the broader medical sector.Speculative2 reports
-
Zacks listed Gilead Sciences as a trending stock, noting that industry performance influences stock trends.Some support2 reports2 developments inside
-
Gilead Sciences stock declined by 3.1% while the broader industry gained 3.2% on June 27, 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Gilead Sciences this week
News at the entities that move Gilead Sciences most-
Norges Bank TransactionalMicron Technology, Norges Bank, and Morgan Stanley are involved in stock purchases and increased holdings as of June 26, 2026, requiring SEC filings.Moves Gilead Sciences
-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Gilead Sciences
-
European Commission StructuralMureșan supports the EU's global vision as the Commission centers the bloc in Brussels amid Canada's geopolitical shift.Moves Gilead Sciences
-
Food and Drug Administration StructuralSummit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Moves Gilead Sciences
-
Merck StructuralModerna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Moves Gilead Sciences
-
Securities and Exchange Commission StructuralBlackRock filed disclosures with the SEC regarding the iShares 0-3 Month Treasury Bond ETF.Moves Gilead Sciences
Connections
The 40 strongest of 320, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Arcellx Structural
Arcellx was acquired by Gilead Sciences in a definitive transaction to integrate its technology into Gilead's portfolio.
-
Kymera Therapeutics Operational
Kymera Therapeutics and Gilead Sciences have entered an exclusive license agreement to co-develop and commercialize molecular glue degraders for cancer.
-
Anu Osinusi Structural
Anu Osinusi is employed as VP of Clinical Development at Gilead Sciences.
-
FDA Structural
The FDA regulates Gilead Sciences, controlling drug trials, approvals, and market access through formal oversight.
-
European Commission Structural
The European Commission grants marketing authorization and regulates Gilead Sciences' pharmaceutical products.
-
Compugen Ltd. Transactional
Compugen licensed the drug candidate GS-0321 to Gilead for development following a partnership agreement.
-
Merck Structural
Gilead relies on Merck's products for combination therapies and the companies are actively partnering on new drug development.
-
Securities and Exchange Commission Structural
Gilead Sciences is subject to formal regulatory oversight and filing requirements imposed by the Securities and Exchange Commission.
Show all 40 connections
-
Eli Lilly and Company Operational
Eli Lilly and Gilead Sciences actively compete against each other in the global pharmaceutical market.
-
Invesco Structural
Invesco maintains a large investment position in Gilead Sciences.
-
Assembly Biosciences (United States) Structural
Gilead Sciences holds the largest shareholder stake and provides funding, licensing rights, and development partnerships to Assembly Biosciences.
-
Ideaya Biosciences (United States) Structural
Gilead supplies Trodelvy to Ideaya Biosciences, and the companies are collaborating on clinical trials.
-
Bristol-Myers Squibb Operational
The companies are active biopharma competitors in specialized therapeutic areas, with evidence of specific supply chain interactions.
-
Galapagos Structural
Galapagos and Gilead Sciences maintain a structural relationship defined by a transformational agreement and board representation.
-
Pan American Health Organization Operational
Gilead Sciences and PAHO collaborate through formal agreements to expedite HIV prevention access.
-
Sanofi Operational
The two companies are engaged in an active collaboration where revenue streams are shared.
-
SEC Structural
Gilead Sciences is subject to regulatory oversight and disclosure requirements enforced by the SEC.
-
SPDR Structural
SPDR holds Gilead Sciences as a major investment position in its assets.
-
Pfizer Operational
Pfizer and Gilead Sciences actively compete in the fragmented HIV drug market and are co-held in the PJP ETF portfolio.
-
Food and Drug Administration Structural
The FDA formally regulates Gilead Sciences, issuing clinical holds and granting product approvals.
-
Moderna Operational
The companies are major players in the biotech sector and actively compete in the market.
-
Amgen Operational
The companies are direct competitors in the biotech industry and are frequently grouped together in market funds and indices.
-
HSBC Operational
HSBC provides financial ratings and price targets for Gilead Sciences, influencing market perception.
-
Merck KGaA Operational
The two companies are current competitors in the fragmented HIV drug market and share a history of collaboration.
-
McKesson Corporation Structural
McKesson acts as a distributor in the supply chain for pharmaceutical products manufactured by Gilead Sciences.
-
Boston Partners Transactional
Boston Partners purchased a new stake in Gilead Sciences shares.
-
World Health Organization Structural
Gilead leverages WHO prequalification processes and partners with global health initiatives to deliver medications.
-
Biogen Operational
The two companies are recognized as peers and actively compete within the therapeutics market.
-
Bank of America Operational
Bank of America provides investment ratings on Gilead Sciences based on its financial performance.
-
Humana Operational
Humana provides insurance coverage for patients prescribed medications from Gilead Sciences.
-
National Comprehensive Cancer Network Operational
NCC review directly influences the preferred status of Gilead's drugs.
-
ABR Mentioned together
ABR tracks and validates financial metrics and brokerage recommendations related to Gilead Sciences.
-
Centers for Disease Control and Prevention Operational
Gilead Sciences uses CDC estimates to track and compare its usage data.
-
AbbVie Operational
The companies actively compete in cell therapy acquisitions and are grouped together in the same investment portfolios.
-
Norges Bank Transactional
Norges Bank acquired a new investment stake in Gilead Sciences shares.
-
Royal Bank of Canada Operational
Royal Bank of Canada actively analyzes Gilead Sciences by raising its target price objective.
-
Flagship Pioneering Transactional
ProFound Therapeutics formed by Flagship Pioneering.
-
Benzinga Mentioned together
Benzinga consistently reports and tracks market performance and operational data regarding Gilead Sciences.
-
Cognizant Operational
Cognizant and Gilead Sciences maintain an active partnership focused on accelerating AI-driven DevOps.
-
Truist Financial Mentioned together
Truist Financial provides financial commentary and price targets for Gilead Sciences.
History
Events by the month they beganOctober 2026
4 events- Amgen and Gilead Sciences are two companies that compete within the biotech industry.
- Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.
- The FDA approved the Bixlenvo HIV regimen developed by Gilead Sciences.
- GRAIL and Gilead Sciences, both healthcare companies, are competing for investment.
September 2026
12 events- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.
- MarketBeat listed Danaher, Dexcom, Medtronic, Gilead Sciences, and Boston Scientific as stocks to watch on September 22, 2026.
- Morgan Stanley provided research notes and an Overweight rating on Gilead Sciences stock on September 20, 2026.
- Gilead Sciences established a strategic alliance and contributed $5 billion, while Lakefront Biotherapeutics acquired assets from Ouro Medicines.
- Gilead Sciences and T. Rowe Price are currently among the largest dividend payers.
- Analyst upgrades and downgrades were noted for General Motors, Gilead Sciences, Emerson Electric, and CrowdStrike on May 22, 2026.
- A conference involving Gilead Sciences and Bayer was held in Philadelphia on September 10, 2026.
- Gilead Sciences acquired Arcellx and presented priorities at a Wells Fargo conference, while also discussing submissions with the FDA and CDC.
- Merdad Parsey, formerly of Gilead Sciences, joined the Sofinnova investment team.
- Gilead Sciences product acceptance paves way for market access, guided by expert opinion in NHS Scotland.
- Gilead Sciences and Grifols traded on the NASDAQ stock exchange on September 8, 2026.
- Gilead Sciences provided an HIV prevention drug consignment to a Zambian hospital, funded by the US.
August 2026
14 events- Executive leadership experience gained at Gilead Sciences, involving Cocrystal Pharma.
- FDA granted designation for a drug under Gibbs' leadership, involving GSK and Gilead Sciences.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Lakefront, in collaboration with Gilead, received Orphan Drug Designation from the FDA for gamgertamig, with trials active globally.
- McDonald's, Walmart, and Gilead Sciences are suggested as resilient safe-haven investments during market turmoil.
- A lawsuit has been filed regarding the importation of foreign-market drugs, involving Gilead Sciences and Meritain Health, Inc.
- A U.S. patient case involving Gilead Sciences originated in Turkey, concerning revenue protection from generic imports.
- Collaboration revenue streams are shared between Sanofi and Gilead Sciences.
- MarketBeat is providing analyst recommendations and comparing two healthcare companies, Gilead Sciences and Pharvaris.
- Gilead Sciences reported earnings, leading Bank of America to reiterate a Buy rating.
- Gilead Sciences, Boston Scientific, McKesson Corporation, and Dexcom are listed as top medical stocks.
- Norges Bank acquired a new stake in Gilead Sciences, while Boston Partners also bought shares, all filed with the SEC.
- Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.
- Benzinga reports on market expectations for Amgen, Pfizer, and Gilead Sciences.
Show 2 earlier months
July 2026
7 events- Top holdings of the IBBQ and IXJ funds were reported, featuring major pharmaceutical companies.
- Gilead Sciences sponsored a session at the ESSENCE Festival.
- Bristol-Myers Squibb and Gilead Sciences are major biopharma firms, with Gilead Sciences recently employing Lena Moran-Adams.
- HSBC upgraded Gilead Sciences stock, citing pessimistic consensus.
- Gilead Sciences received FDA approval and preferred status via NCC review for its drug Trodelvy.
- An investor made multiple stock purchases in companies including Cencora, Gilead Sciences, GE Aerospace, and American Express.
- Norges Bank acquired a new position in Gilead Sciences shares, triggering institutional ownership filing requirements with the SEC.
June 2026
23 events- Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.
- Benzinga generated content regarding the financial performance of Gilead Sciences on June 17, 2026.
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- GSK and EXEL are developing treatments for PBC, and the FDA granted accelerated approval to Gilead Sciences for related therapies.
- The iShares Nasdaq Biotechnology ETF (IBB) was reported to hold significant shares of Amgen, Vertex Pharmaceuticals, and Gilead Sciences.
- Gilead Sciences received FDA endorsement and product approvals in Norway, Iceland, and Liechtenstein on August 27, 2025, while navigating Trump's tariffs.
- Gilead Sciences' drug Trodelvy received marketing authorization from the European Commission for use in EU member states.
- Gilead Sciences filed its required 13F reports with the Securities and Exchange Commission on June 22, 2026.
- Phase 3 results showed efficacy in primary biliary cholangitis involving Alp and Gilead Sciences.
- Gilead Sciences supports Native Son Awards featuring Terrell Carter, with a fellowship debut scheduled in New York.
- Cantor Fitzgerald issued research notes on Gilead Sciences (GILD) stock, which are being aggregated by MarketBeat.
- Multiple investment firms, including Paulson Wealth Management and Alpha Cubed Investments, have made various transactions regarding their holdings in Gilead Sciences.
- Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
- Westfield Capital Management acquired a new stake in Gilead Sciences shares, concurrent with an SEC filing on June 6, 2026.
- Gilead Sciences developed Yeytuo for HIV prevention, which received authorization from the European Commission following EMA assessment.
- U.S. purchases PEPFAR doses and Gilead sells drugs at no profit following Trump administration's foreign aid cuts.
- Incyte and Gilead Sciences are discussed in the context of commercializing innovative medicines for life-threatening diseases.
- Gilead Sciences holds the largest shareholder stake in Assembly Biosciences, followed by Alexander Schornstein and The Vanguard Group.
- FDA fast-tracking of a therapy involving Precision BioSciences, Arrowhead Pharmaceuticals, and Gilead Sciences began on July 1, 2025.
- Kymera entered an exclusive option and license agreement with Gilead Sciences.
- Gilead Sciences is identified as a participant within the broader medical sector.
- Zacks listed Gilead Sciences as a trending stock, noting that industry performance influences stock trends.
- Gilead Sciences stock declined by 3.1% while the broader industry gained 3.2% on June 27, 2025.